Study guide

6.1 Terminal Sterilization vs. Sterilizing Filtration

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

6.1 Terminal Sterilization vs. Sterilizing Filtration

Key Takeaways Explain This Topic AI

USP <797> prefers terminal sterilization in the final sealed container when the CSP and its container-closure system can tolerate it; sterilizing filtration is used for heat-labile preparations.

Injectable CSPs containing nonsterile components (or exposed to nonsterile devices) must be sterilized within 6 hours after preparation is completed, to limit endotoxin formation.

Steam sterilization is verified with biological indicators such as Geobacillus stearothermophilus with every run or load; USP cites 20 to 60 minutes at 121 °C and 15 psi as an example, depending on load.

Dry heat depyrogenation must be shown, initially and at least annually, to give at least a 3-log endotoxin reduction using endotoxin challenge vials. Bacillus atrophaeus indicators verify dry heat sterilization runs.

Sterilizing filters are 0.22 µm or smaller and retain at least 10^7 Brevundimonas diminuta per cm². Each filter must pass integrity testing; after a failure the CSP is discarded or, after investigation, refiltered no more than one more time.

Last updated: September 2026

Sterilization Modalities in Sterile Compounding

Sterilization is the validated process by which all viable microorganisms (including bacterial vegetative cells, fungal spores, and bacterial endospores) are eliminated or destroyed. USP General Chapter <797> treats terminal sterilization in the final sealed container as the preferred method whenever the CSP and its container-closure system can tolerate it. Sterilizing filtration is used for heat-labile preparations. Timing matters too: an injectable CSP that contains nonsterile components, or touches nonsterile devices, must be sterilized within 6 hours after preparation is completed , before bacteria can multiply and shed endotoxin. The SOPs must describe each cycle (temperature, pressure, duration, permitted loads), how biological indicators and endotoxin challenge vials are used, and how personnel are trained.

Sterility Assurance Level (SAL)

Sterilization processes are designed to achieve a Sterility Assurance Level (SAL) of 10 − 6 10^{-6} 1 0 − 6 , meaning that the theoretical probability of a single surviving viable microorganism in or on a sterilized unit is less than one in one million ( 1 in 1 , 000 , 000 1\text{ in }1,000,000 1 in 1 , 000 , 000 ).

  • Terminal Sterilization Methods
  • 1. Saturated Steam Sterilization (Autoclaving)

Mechanism : Denatures and coagulates essential cellular proteins and microbial enzymes through moist heat transferred via condensing saturated steam under pressure.

Standard Cycle : Saturated steam at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C ( 250 ∘ F 250^\circ\text{F} 25 0 ∘ F ) and 15 psi 15\,\text{psi} 15 psi , for a time proven with biological indicators. USP <797> gives 20 to 60 minutes as an example, depending on the volume or size of the CSP. Solutions are passed through a filter of 1.2 µm or smaller before filling, sealed containers must be able to generate steam internally, and a calibrated recorder documents each cycle.

Physical Parameters :

D D D -Value (Decimal Reduction Time) : The time in minutes required at a specific temperature to reduce a microbial population by 90% (1-log reduction).

Z Z Z -Value : The temperature change (in degrees Celsius) required to change the D D D -value by a factor of 10.

F 0 F_0 F 0 ​ Value : The equivalent lethality delivered to a container at 121 ∘ C 121^\circ\text{C} 12 1 ∘ C . A minimum F 0 F_0 F 0 ​ of 8 to 15 minutes is standard for terminal autoclave cycles.

Biological Indicator (BI) : Spores of Geobacillus stearothermophilus ( 10 6 10^6 1 0 6 spores per carrier), an extremely heat-resistant thermophilic spore-former.

2. Dry Heat Sterilization & Depyrogenation

Mechanism : Kills microbes through cellular protein oxidation and irreversible macromolecular desiccation.

Depyrogenation : Endotoxins (lipopolysaccharides from Gram-negative bacterial walls) are remarkably heat-stable and survive standard autoclaving. Destroying endotoxins requires dry heat depyrogenation:

Typical Cycle : Depyrogenation ovens commonly run at about 250 ∘ C 250^\circ\text{C} 25 0 ∘ C . Dry heat sterilization , which is a different goal, is usually done at 160 ∘ C 160^\circ\text{C} 16 0 ∘ C or higher .

Depyrogenation Standard : The cycle must be shown, initially and at least annually, to achieve at least a 3-log (99.9%) reduction in endotoxin using Endotoxin Challenge Vials (ECVs). It must be re-established whenever the load, duration or temperature changes. Items that cannot take the heat are depyrogenated by repeated rinsing with sterile, nonpyrogenic water.

Biological Indicator for dry heat sterilization runs : Spores of Bacillus atrophaeus (formerly Bacillus subtilis ), used with every run or load.

Sterilizing Filtration for Heat-Labile Preparations

When a drug is thermolabile (e.g., proteins, peptides, heat-sensitive antibiotics, ophthalmics), terminal heat sterilization causes chemical breakdown. In these cases, the solution must be passed through a sterilizing-grade membrane filter into a sterile container inside an ISO Class 5 PEC.

Filter Specifications under USP <797>

Pore Size : Must possess a nominal pore rating of 0.22 μ m 0.22\,\mu\text{m} 0.22 μ m or 0.2 μ m 0.2\,\mu\text{m} 0.2 μ m .

Microbial Challenge Retention : Certified to retain a minimum challenge of 10 7 microorganisms per square centimeter 10^7\text{ microorganisms per square centimeter} 1 0 7 microorganisms per square centimeter of effective filter area of Brevundimonas diminuta (ATCC 19146), an unusually tiny bacterium ( 0.3 μ m × 0.9 μ m 0.3\,\mu\text{m} \times 0.9\,\mu\text{m} 0.3 μ m × 0.9 μ m ).

Membrane Compatibility : Filter membranes (PES, PVDF, PTFE, nylon) must be selected based on drug compatibility, low protein binding, and surfactant tolerance.

Mandatory Post-Filtration Filter Integrity Testing

A sterile filter membrane can rupture, deform under excessive differential pressure, or contain micro-pinholes invisible to the naked eye. Therefore, USP <797> establishes an absolute mandate:

Important

Every sterilizing-grade filter assembly used to compound a CSP batch must undergo post-filtration integrity testing immediately following compounding.

The Bubble Point Test

The used filter membrane is wetted with the compounding liquid (or sterile water).

Upstream gas (air or nitrogen) pressure is gradually increased.

The Bubble Point Pressure is the specific pressure at which gas overcomes the surface tension of the fluid filling the membrane pores, producing a continuous stream of bubbles downstream.

Pass/Fail Standard : The measured bubble point must meet or exceed the minimum the filter manufacturer states for that membrane and wetting fluid. If several filters are used in one process, each must pass.

Protocol Following a Failed Filter Integrity Test

If the filter fails the bubble point test, sterility of the filtrate cannot be assured, and the CSP cannot be released as it is. USP <797> requires it to be discarded, or refiltered for sterilization no more than one additional time after the cause is investigated and an appropriate filter is chosen. The new filter must also pass integrity testing. If a CSP is known to carry heavy particulate matter, a larger-pore prefilter (for example, 1.2 µm) goes upstream of the sterilizing filter.

Thermal Lethality Kinetics: D-Value, z-Value, and F0 Modeling

Terminal moist heat sterilization cycles are engineered using mathematical kinetic models to ensure reproducible destruction of heat-resistant microbial endospores without degrading thermolabile formulation components:

Mathematical Principles of Microbial Inactivation

D-Value (Decimal Reduction Time) : The time required in minutes at a specified temperature to reduce the surviving microbial population by 90% (a one-log reduction). For Geobacillus stearothermophilus in neutral aqueous media at 121°C, D-values typically range from 1.5 to 2.0 minutes.

z-Value : The temperature change (in degrees Celsius) required to change the D-value by a factor of 10. For steam sterilization, the standard compendial z-value is 10°C.

F0 Value (Equivalent Lethality) : The integrated equivalent exposure time in minutes at 121.1°C (250°F). Cycles are designed around an F0 target, commonly 8 to 15 minutes, and then verified with biological indicators to support a Sterility Assurance Level (SAL) of 10 − 6 10^{-6} 1 0 − 6 .

Overkill vs. Bioburden-Based Sterilization Cycles

Overkill Cycle : Delivers an F0 of at least 15 minutes, achieving an at least 12-log reduction of resistant endospores regardless of initial bioburden.

Bioburden-Based Cycle : Used for heat-sensitive drug entities, calibrated to deliver an SAL of 10 − 6 10^{-6} 1 0 − 6 based on pre-sterilization bioburden enumeration and resistance profiling.